MCID: DMN031
MIFTS: 59

Dementia, Lewy Body

Categories: Genetic diseases, Rare diseases, Neuronal diseases, Mental diseases

Aliases & Classifications for Dementia, Lewy Body

MalaCards integrated aliases for Dementia, Lewy Body:

Name: Dementia, Lewy Body 54 24 13
Lewy Body Dementia 54 12 50 24 51 71 29 14
Lewy Body Disease 12 50 52 41 42 69
Diffuse Lewy Body Disease 12 50 24 71
Dlb 50 24 71
Autosomal Dominant Diffuse Lewy Body Disease 50 69
Dementia with Lewy Bodies 12 51
Diffuse Lewy Body Disease with Gaze Palsy 71
Lewy Body Variant of Alzheimer Disease 71
Senile Dementia of the Lewy Body Type 12
Lewy Body Type Senile Dementia 71
Dysphasic Dementia Hereditary 71
Cortical Lewy Body Disease 71
Dementia Lewy Body 71
Lewy Bodies 29

Characteristics:

OMIM:

54
Inheritance:
autosomal dominant

Miscellaneous:
onset in the sixth or seventh decades
phenotypic overlap with parkinson disease
allelic disorder to parkinson disease-1 (park1, )


HPO:

32
dementia, lewy body:
Inheritance autosomal dominant inheritance


Classifications:



Summaries for Dementia, Lewy Body

NINDS : 51 Dementia with Lewy bodies (DLB) is one of the most common types of progressive dementia. The central features of DLB include progressive cognitive decline, “fluctuations” in alertness and attention, visual hallucinations, and parkinsonian motor symptoms, such as slowness of movement, difficulty walking, or rigidity.  People may also suffer from depression.  The symptoms of DLB are caused by the build-up of Lewy bodies – accumulated bits of alpha-synuclein protein -- inside the nuclei of neurons in areas of the brain that control particular aspects of memory and motor control.  Researchers don’t know exactly why alpha-synuclein accumulates into Lewy bodies or how Lewy bodies cause the symptoms of DLB, but they do know that alpha-synuclein accumulation is also linked to Parkinson's disease, multiple system atrophy, and several other disorders, which are referred to as the "synucleinopathies." The similarity of symptoms between DLB and Parkinson’s disease, and between DLB and Alzheimer’s disease, can often make it difficult for a doctor to make a definitive diagnosis. In addition, Lewy bodies are often also found in the brains of people with Parkinson's and Alzheimer’s diseases.  These findings suggest that either DLB is related to these other causes of dementia or that an individual can have both diseases at the same time.  DLB usually occurs sporadically, in people with no known family history of the disease. However, rare familial cases have occasionally been reported.

MalaCards based summary : Dementia, Lewy Body, also known as lewy body dementia, is related to parkinson disease, late-onset and parkinson disease 1, and has symptoms including delusions, parkinsonism and dementia. An important gene associated with Dementia, Lewy Body is SNCA (Synuclein Alpha), and among its related pathways/superpathways are Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. and Circadian entrainment. The drugs Armodafinil and Modafinil have been mentioned in the context of this disorder. Affiliated tissues include brain, eye and testes, and related phenotypes are homeostasis/metabolism and behavior/neurological

NIH Rare Diseases : 50 lewy body dementia is one of the most common forms of progressive dementia. people affected by this condition may experience a variety of symptoms such as changes in alertness and attention; hallucinations; problems with movement and posture; muscle stiffness; confusion; and/or memory loss. although the exact cause of lewy body dementia is poorly understood, symptoms are thought to result when clumps of a protein called alpha-synuclein ("lewy bodies") accumulate in the brain. lewy body dementia usually occurs sporadically in people with no family history of the condition. rarely, more than one family member may be affected. there is currently no cure for lewy body dementia; however, medications may be available to help manage the associated symptoms. last updated: 11/5/2015

UniProtKB/Swiss-Prot : 71 Dementia Lewy body: A neurodegenerative disorder characterized by mental impairment leading to dementia, parkinsonism, fluctuating cognitive function, visual hallucinations, falls, syncopal episodes, and sensitivity to neuroleptic medication. Brainstem or cortical intraneuronal accumulations of aggregated proteins (Lewy bodies) are the only essential pathologic features. Patients may also have hippocampal and neocortical senile plaques, sometimes in sufficient number to fulfill the diagnostic criteria for Alzheimer disease.

MedlinePlus : 41 lewy body disease is one of the most common causes of dementia in the elderly. dementia is the loss of mental functions severe enough to affect normal activities and relationships. lewy body disease happens when abnormal structures, called lewy bodies, build up in areas of the brain. the disease may cause a wide range of symptoms, including changes in alertness and attention hallucinations problems with movement and posture muscle stiffness confusion loss of memory lewy body disease can be hard to diagnose, because parkinson's disease and alzheimer's disease cause similar symptoms. scientists think that lewy body disease might be related to these diseases, or that they sometimes happen together. lewy body disease usually begins between the ages of 50 and 85. the disease gets worse over time. there is no cure. treatment focuses on drugs to help symptoms. nih: national institute of neurological disorders and stroke

OMIM : 54
Dementia with Lewy bodies (DLB) is a neurodegenerative disorder clinically characterized by dementia and parkinsonism, often with fluctuating cognitive function, visual hallucinations, falls, syncopal episodes, and sensitivity to neuroleptic medication. Pathologically, Lewy bodies are present in a pattern more widespread than usually observed in Parkinson disease (see PD; 168600). Alzheimer disease (AD; 104300)-associated pathology and spongiform changes may also be seen (McKeith et al., 1996; Mizutani, 2000; McKeith et al., 2005). (127750)

Disease Ontology : 12 A dementia and a synucleinopathy that is characterized by the development of abnormal proteinaceous (alpha-synuclein) cytoplasmic inclusions, called Lewy bodies, throughout the brain that results in progressive decline in mental abilities.

Wikipedia : 72 Dementia with Lewy bodies (DLB) is a type of dementia that worsens over time. Additional symptoms may... more...

Related Diseases for Dementia, Lewy Body

Diseases related to Dementia, Lewy Body via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 65)
id Related Disease Score Top Affiliating Genes
1 parkinson disease, late-onset 28.5 ACHE APOE APP BCHE CYP2D6 GBA
2 parkinson disease 1 27.6 ACHE ADAMTS2 APOE APP BCHE CYP2D6
3 parkinson disease 4 11.6
4 dementia 11.3
5 corticobasal degeneration 11.3
6 13q12.3 microdeletion syndrome 10.9 GBA LRRK2 SNCA
7 acquired purpura fulminans 10.8 APOE MAPT
8 hfe-associated hereditary hemochromatosis 10.7 APOE PRNP
9 microcephaly 18, primary, autosomal dominant 10.7 SLC18A2 SLC6A3 SNCA
10 atrioventricular septal defect 5 10.7 APP MAPT SNCA
11 limited scleroderma 10.6 APOE APP MAPT
12 penis basal cell carcinoma 10.6 MAPT PRNP SLC6A3
13 basilar impression, primary 10.6 MAPT RPS27A SNCA
14 seow najjar syndrome 10.6 APOE MAPT RPS27A
15 bladder hepatoid adenocarcinoma 10.6 SLC18A2 SLC6A3 SNCA
16 thyrotropin-releasing hormone deficiency 10.5 LRRK2 PRKN SLC6A3 SNCA
17 riedel's fibrosing thyroiditis 10.5 LRRK2 MAOB MAPT SNCA
18 parkinson disease 10 10.5 LRRK2 PARK7 PRKN SNCA
19 celiac disease 12 10.5 LRRK2 PARK7 PRKN SNCA
20 cough headache 10.5 GBA MAPT RPS27A
21 ceroid lipofuscinosis, neuronal, 11 10.5 MAPT RPS27A
22 hypogonadotropic hypogonadism without anosmia, x-linked 10.5 ACHE TH
23 perry syndrome 10.5 SLC18A2 SLC6A3 SNCA TH
24 meckel syndrome 10 10.5 APOE APP BCHE MAPT
25 fastkd2-related infantile mitochondrial encephalomyopathy 10.5 GBA LRRK2 MAPT PRKN SNCA
26 bladder cancer, childhood 10.5 ACHE APOE APP MAPT
27 pediatric myxoid chondrosarcoma 10.4 APP MAPT PRNP
28 proteus syndrome, somatic 10.4 RPS27A SLC6A3 SNCA
29 piebald trait, kit-related 10.4 GBA LRRK2 MAPT PARK7 SNCA
30 cardiomyopathy, dilated, 1u 10.4 APOE MAPT RPS27A SNCA
31 pyogenic arthritis, pyoderma gangrenosum and acne 10.4 ACHE MAOB SNCA TH
32 waldenstroem's macroglobulinemia 10.4 GBA LRRK2 PARK7 PRKN SNCA
33 prion disease with protracted course 10.4 APOE MAPT PRNP
34 akinetic mutism 10.4 APOE APP
35 cervical squamous cell carcinoma 10.4 APP PRNP
36 pulmonary systemic sclerosis 10.4 ADAMTS2 APOE APP MAPT
37 polyneuropathy, hearing loss, ataxia, retinitis pigmentosa, and cataract 10.4 APOE APP PRNP
38 3mc syndrome 10.3 ACHE BCHE MAPT PRNP
39 ectodermal dysplasia 13, hair/tooth type 10.3 LRRK2 PARK7 PRKN SNCA TH
40 allergic bronchopulmonary aspergillosis, familial 10.3 APOE APP MAPT RPS27A
41 mucopolysaccharidosis iii 10.3 MAPT PRKN RPS27A SNCA
42 carotid body cancer 10.3 ACHE APOE APP BCHE MAPT
43 sebaceous gland disease 10.2 ACHE LRRK2 RPS27A SLC6A3 SNCA
44 erb-duchenne and dejerine-klumpke palsies 10.2 PRKN SNCA
45 sparc-related osteogenesis imperfecta 10.2 LRRK2 MAPT PARK7 PRKN SNCA SNCAIP
46 chronic conjunctivitis 10.2 CYP2D6 MAOB SLC18A2 SLC6A3
47 hyperekplexia, hereditary 1, autosomal dominant or recessive 10.2 APP MAPT PRNP RPS27A SNCA
48 partial motor epilepsy 10.2 MAOB SLC18A2 TH
49 nosophobia 10.2 APOE APP LRRK2 MAPT PRNP SNCA
50 craniosynostosis, adelaide type 10.0 CYP2D6 MAOB SLC18A2 SLC6A3 TH

Graphical network of the top 20 diseases related to Dementia, Lewy Body:



Diseases related to Dementia, Lewy Body

Symptoms & Phenotypes for Dementia, Lewy Body

Symptoms via clinical synopsis from OMIM:

54

Neurologic- Central Nervous System:
delusions
parkinsonism
progressive dementia
visual hallucinations
fluctuations in consciousness
more

Clinical features from OMIM:

127750

Human phenotypes related to Dementia, Lewy Body:

32
id Description HPO Frequency HPO Source Accession
1 delusions 32 HP:0000746
2 parkinsonism 32 HP:0001300
3 dementia 32 HP:0000726
4 visual hallucinations 32 HP:0002367
5 fluctuations in consciousness 32 HP:0007159

UMLS symptoms related to Dementia, Lewy Body:


back pain, headache, pain, sciatica, seizures, syncope, tremor, chronic pain, hallucinations, visual, vertigo/dizziness, sleeplessness

MGI Mouse Phenotypes related to Dementia, Lewy Body:

44 (show all 13)
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.38 ACHE APOE APP BCHE GBA LRRK2
2 behavior/neurological MP:0005386 10.37 LRRK2 MAOB MAPT PARK7 PRKN PRNP
3 growth/size/body region MP:0005378 10.34 TH ACHE ADAMTS2 APOE APP GBA
4 cellular MP:0005384 10.32 APOE APP GBA LRRK2 MAOB MAPT
5 mortality/aging MP:0010768 10.28 GBA LRRK2 MAPT PRKN PRNP SLC18A2
6 nervous system MP:0003631 10.24 MAPT PARK7 PRKN PRNP SLC18A2 SLC6A3
7 integument MP:0010771 10.2 ADAMTS2 APOE APP GBA LRRK2 MAPT
8 no phenotypic analysis MP:0003012 10.02 ACHE APOE APP LRRK2 MAPT PRKN
9 muscle MP:0005369 10.01 ACHE APOE APP MAPT PRKN PRNP
10 normal MP:0002873 9.96 ADAMTS2 APP GBA LRRK2 MAPT PRNP
11 respiratory system MP:0005388 9.7 ACHE ADAMTS2 APOE GBA LRRK2 PRKN
12 skeleton MP:0005390 9.61 ADAMTS2 APOE GBA LRRK2 PRKN PRNP
13 taste/olfaction MP:0005394 9.02 APOE MAPT SLC18A2 SLC6A3 SNCA

Drugs & Therapeutics for Dementia, Lewy Body

Drugs for Dementia, Lewy Body (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 60)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Armodafinil Approved, Investigational Phase 4 112111-43-0
2
Modafinil Approved, Investigational Phase 4 68693-11-8 4236
3
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
4
Donepezil Approved Phase 4,Phase 3,Phase 2 120014-06-4 3152
5
Memantine Approved, Investigational Phase 4,Phase 2 19982-08-2 4054
6
Acetaminophen Approved Phase 4 103-90-2 1983
7
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7 40400 644073
8
Iodine Investigational Phase 4 7553-56-2 807
9
Corticosterone Experimental Phase 4 50-22-6 5753
10 Central Nervous System Stimulants Phase 4
11 Cytochrome P-450 CYP3A Inducers Phase 4
12 Wakefulness-Promoting Agents Phase 4
13 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1
14 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
15 Cholinergic Agents Phase 4,Phase 3,Phase 2
16 Cholinesterase Inhibitors Phase 4,Phase 3,Phase 2
17 Nootropic Agents Phase 4,Phase 3,Phase 2
18 Antiparkinson Agents Phase 4,Phase 2
19 Excitatory Amino Acid Antagonists Phase 4,Phase 2
20 Excitatory Amino Acids Phase 4,Phase 2
21 Analgesics Phase 4
22 Analgesics, Non-Narcotic Phase 4
23 Analgesics, Opioid Phase 4
24 Antipyretics Phase 4
25 Central Nervous System Depressants Phase 4
26 Narcotic Antagonists Phase 4
27 Narcotics Phase 4
28 Peripheral Nervous System Agents Phase 4,Phase 3
29 Pharmaceutical Solutions Phase 4
30 cadexomer iodine Phase 4
31 Anti-Inflammatory Agents Phase 4
32 Fluorodeoxyglucose F18 Phase 4
33 Calamus Nutraceutical Phase 4
34
Galantamine Approved Phase 3 357-70-0 9651
35 Autonomic Agents Phase 3
36 Protective Agents Phase 3
37 Dopamine agonists Phase 1, Phase 2
38
Acetylcholine Approved 51-84-3 187
39
Rivastigmine Approved, Investigational 123441-03-2 77991
40
Acetylcysteine Approved, Investigational 616-91-1 12035
41
Dextromethorphan Approved 125-71-3 5360696 5362449
42
Quinidine Approved 56-54-2 441074
43
Menthol Approved 2216-51-5 16666
44
Ethanol Approved 64-17-5 702
45
Vitamin D Approved, Nutraceutical, Vet_approved 1406-16-2
46
2-Phenylethanol Experimental 60-12-8 6054
47 Vasodilator Agents
48 Neuroprotective Agents
49 Dihydroxyphenylalanine Early Phase 1
50 Fluorides Early Phase 1

Interventional clinical trials:

(show top 50) (show all 84)

id Name Status NCT ID Phase Drugs
1 "Pilot Study of Armodafinil in Patients With Dementia With Lewy Bodies" Completed NCT01023672 Phase 4 Armodafinil
2 Memantine Versus Placebo in Parkinson's Disease Dementia or Dementia With Lewy Bodies Completed NCT00855686 Phase 4 Memantine;Placebo
3 Efficacy of Pain Treatment on Depression in Patients With Dementia Completed NCT02267057 Phase 4 Paracetamol;Buprenorphine;Paracetamol placebo;Buprenorphine placebo
4 A Post-Marketing Clinical Study of Aricept in Patients With Dementia With Lewy Bodies (DLB) Recruiting NCT02345213 Phase 4 E2020;Placebo
5 DaTSCAN Imaging in Aging and Neurodegenerative Disease Enrolling by invitation NCT01453127 Phase 4 I-123 Ioflupane solution injection prior to SPECT scan (DaTscan)
6 Imaging of Brain Amyloid Plaques in the Aging Population Enrolling by invitation NCT00950430 Phase 4 Pittsburgh Compound B (C-11 PiB);F-18 FDG;Tau (18-F-AV-1451)
7 Evaluating the Effects of Music Interventions on Hospitalised People With Dementia Unknown status NCT00448318 Phase 2, Phase 3
8 Donepezil Treatment of Psychotic Symptoms in Dementia Patients Unknown status NCT00190021 Phase 3 donepezil
9 Safety and Efficacy of Galantamine in Patients With Dementia With Lewy Bodies Completed NCT00230997 Phase 3 Galantamine
10 A Study of E2020 in Patients With Dementia With Lewy Bodies (DLB), Followed by a Long-term Extension Phase Completed NCT01278407 Phase 3 Donepezil 5 mg;Donepezil 10 mg;Donepezil matched placebo
11 Dopamine Transporter Scintigraphy Imaging (DAT-Imaging) in Patients With Lewy Body Dementia Completed NCT00209456 Phase 3 DatSCAN
12 Oculomotor Testing in the Differential Diagnosis of Dementia Completed NCT01577394 Phase 3
13 Long-Term Extension Study of Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: HEADWAY-DLB Extension Enrolling by invitation NCT02928445 Phase 2, Phase 3 RVT-101 35 mg;RVT-101 70 mg
14 A Long-term, Extension Study of E2020 in Patients With Dementia With Lewy Bodies Completed NCT00598650 Phase 2 E2020
15 A Double-blind Study of E2020 (Donepezil Hydrochloride) in Patients With Dementia With Lewy Bodies (DLB) (Study E2020-J081-431) Completed NCT00543855 Phase 2 3 mg Donepezil hydrochloride;5 mg Donepezil hydrochloride;10 mg Donepezil hydrochloride;Placebo
16 Efficacy and Safety of Memantine for Parkinson's Disease Dementia (PDD) and Dementia With Lewy Bodies (DLB) Completed NCT00630500 Phase 2 Memantine;Placebo
17 A Trial of 18F-AV-133 and 18F-AV-45 Positron Emission Tomography (PET) Completed NCT01503944 Phase 1, Phase 2 18F-AV-133;18F-AV-45
18 Efficacy of 1072nm Infrared Stimulation on Executive Functioning in Dementia Completed NCT01059877 Phase 1, Phase 2
19 Imaging Inflammation in Patients With Parkinson's Disease Dementia or Dementia With Lewy Bodies Recruiting NCT02702102 Phase 2 11C-PBR28
20 Study Evaluating Nelotanserin for Treatment of REM Sleep Behavior Disorder in Subjects With Dementia (DLB or PDD) Recruiting NCT02708186 Phase 2 Nelotanserin;Placebo
21 Effect of Donepezil on Cognition in Parkinson's Disease With Mild Cognitive Impairment (PD-MCI) Recruiting NCT02450786 Phase 2 Donepezil
22 Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parkinson's Disease Recruiting NCT02954978 Phase 2 Placebo Oral Capsule;Nilotinib 150mg oral capsule [Tasigna];Nilotinib 300mg oral capsule [Tasigna]
23 Study Evaluating Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: The HEADWAY-DLB Study Active, not recruiting NCT02669433 Phase 2 RVT-101 35 mg;RVT-101 70 mg;Placebo
24 Study Evaluating Nelotanserin for Treatment of Visual Hallucinations in Subjects With Lewy Body Dementia Active, not recruiting NCT02640729 Phase 2 Nelotanserin;Placebo
25 Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia Active, not recruiting NCT02910102 Phase 2 RVT-101 35 mg;Placebo
26 Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder Enrolling by invitation NCT02871427 Phase 2 Nelotanserin
27 Nilotinib in Cognitively Impaired Parkinson Disease Patients 001 Completed NCT02281474 Phase 1 Nilotinib
28 Effects of Nucleus Basalis of Meynert Stimulation on Cognitive Disorders in Dementia With Lewy Bodies Recruiting NCT01340001 Phase 1
29 Alpha-synuclein in Cerebrospinal Fluid to Differentiate Alzheimer's Disease From Lewy Body Disease. Unknown status NCT01876459
30 Construction-LBD (Constructional Apraxia in Alzheimer's Disease (AD) and Lewy Body's Dementia (LBD)) Unknown status NCT01993628
31 Attention Modulation for Treatment of Parkinson's Disease and Dementia With Lewy Bodies Unknown status NCT01256905 Armodafinil
32 The Sunnybrook Dementia Study: Mapping Brain Changes in Alzheimer's, Vascular and Other Dementias Unknown status NCT01800214
33 Gait and REM Sleep Behavior Disorder Unknown status NCT02554331
34 Study of MRI 3Tesla Infusion Without Arterial Spin Labeling Injection (ASL) in Cognitive Atypical and Comparison to the FDG-PET Unknown status NCT02058043
35 Imaging of Vesicular Acetylcholine and Dopamine Transporters in Dementia With Lewy Bodies Completed NCT00917709
36 Diagnostic of Lewy Body Dementia by Combining Scintigraphy (SPECT) Using a Specific Transporter and Magnetic Resonance Imaging (MRI) Completed NCT00820937
37 Deep Brain Stimulation for Patients With Dementia With Lewy Bodies Completed NCT02263937
38 A Genetic and Perfusion Study of Response to Cognitive Enhancers in Lewy Body Disease Completed NCT01944436 Cholinesterase Inhibitors (Rivastigmine, Aricept, Galantamine)
39 Donepezil Therapy and Changes of Symptoms and Glucose Metabolism in Patients With Dementia With Lewy Bodies (DLB) Completed NCT00776347 Donepezil;Donepezil
40 Treadmill Walking in Individuals With Dementia With Lewy Bodies and Huntington's Disease Completed NCT02268617
41 A Longitudinal Multidimensional Population Study on Brain Aging Completed NCT01345110
42 Research of Biomarkers in Parkinson Disease Completed NCT00465790 Early Phase 1
43 Systematic Care for Informal Caregivers of Dementia Patients: An Efficient Approach? Completed NCT00147693
44 Predictive and Diagnostic Value of Tau and Beta-amyloid Markers in the Dementia of Parkinson's Disease Completed NCT02243982 Early Phase 1
45 Blood Gene Expression Signature in Patients Diagnosed With Probable Alzheimer's Disease Compared to Patients Suffering From Other Types of Dementia Completed NCT00880347
46 Assessment of Social-emotional Functioning in Neurological Diseases Completed NCT01339130
47 Visual Function During Gait in Parkinson's Disease: Impact of Cognition and Response to Visual Cues Completed NCT02610634
48 Enhancing Care Coordination: Hospital to Home for Cognitively Impaired Older Adults and Their Caregivers Completed NCT00294307
49 COMPARATIVE EFFECTIVENESS OF MCI and DEMENTIA TREATMENTS IN A COMMUNITY-BASED DEMENTIA PRACTICE Completed NCT02860338
50 LESCOD: "Lewy Body Screening in Cognitive Disorders" Recruiting NCT02263287

Search NIH Clinical Center for Dementia, Lewy Body

Cochrane evidence based reviews: lewy body disease

Genetic Tests for Dementia, Lewy Body

Genetic tests related to Dementia, Lewy Body:

id Genetic test Affiliating Genes
1 Lewy Body Dementia 29
2 Lewy Bodies 29
3 Dementia, Lewy Body 24 SNCA

Anatomical Context for Dementia, Lewy Body

MalaCards organs/tissues related to Dementia, Lewy Body:

39
Brain, Eye, Testes, Colon

Publications for Dementia, Lewy Body

Articles related to Dementia, Lewy Body:

id Title Authors Year
1
The effects of behavioral and psychological symptoms on caregiver burden in frontotemporal dementia, Lewy body dementia, and Alzheimer's disease: clinical experience in China. ( 26882509 )
2016
2
Cognitive fluctuations in connection to dysgraphia: a comparison of Alzheimer's disease with dementia Lewy bodies. ( 25848239 )
2015
3
Parkinson's disease with dementia, lewy-body disorders and alpha-synuclein: recent advances and a case report. ( 21560084 )
2011

Variations for Dementia, Lewy Body

UniProtKB/Swiss-Prot genetic disease variations for Dementia, Lewy Body:

71
id Symbol AA change Variation ID SNP ID
1 SNCA p.Glu46Lys VAR_022703 rs104893875

ClinVar genetic disease variations for Dementia, Lewy Body:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 GBA NM_001005741.2(GBA): c.1226A> G (p.Asn409Ser) single nucleotide variant Pathogenic/Likely pathogenic,risk factor rs76763715 GRCh37 Chromosome 1, 155205634: 155205634
2 SNCB NM_001001502.2(SNCB): c.208G> A (p.Val70Met) single nucleotide variant Pathogenic rs104893936 GRCh37 Chromosome 5, 176053473: 176053473
3 SNCB NM_001001502.2(SNCB): c.368C> A (p.Pro123His) single nucleotide variant Pathogenic rs104893937 GRCh37 Chromosome 5, 176048219: 176048219
4 SNCA NM_000345.3(SNCA): c.136G> A (p.Glu46Lys) single nucleotide variant Pathogenic rs104893875 GRCh37 Chromosome 4, 90749321: 90749321
5 SNCA SNCA, DUPLICATION duplication Pathogenic

Expression for Dementia, Lewy Body

Search GEO for disease gene expression data for Dementia, Lewy Body.

Pathways for Dementia, Lewy Body

Pathways related to Dementia, Lewy Body according to GeneCards Suite gene sharing:

(show all 17)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.19 APOE APP LRRK2 MAPT PARK7 PRKN
2
Show member pathways
12.6 ACHE MAOB SLC18A2 SLC6A3 TH
3
Show member pathways
12.52 PARK7 PRKN SLC6A3 SNCA SNCAIP
4 11.83 APOE APP LRRK2 MAPT PARK7 PRKN
5
Show member pathways
11.8 MAOB SLC18A2 SLC6A3 TH
6 11.76 APP CYP2D6 MAOB SLC18A2
7 11.62 LRRK2 PARK7 PRKN SLC6A3 SNCA SNCAIP
8 11.43 APP MAPT PRNP
9 11.32 APOE APP MAPT
10
Show member pathways
11.29 ACHE SLC6A3 TH
11 11.2 ACHE APOE CYP2D6
12 11.02 SLC18A2 SLC6A3 TH
13 10.94 MAOB PARK7 PRKN SLC6A3 SNCA TH
14
Show member pathways
10.93 ACHE BCHE SLC6A3
15 10.71 MAOB TH
16 10.64 PRKN RPS27A
17 10.63 ACHE TH

GO Terms for Dementia, Lewy Body

Cellular components related to Dementia, Lewy Body according to GeneCards Suite gene sharing:

(show all 17)
id Name GO ID Score Top Affiliating Genes
1 synapse GO:0045202 9.95 ACHE APP LRRK2 SNCA SNCB
2 dendrite GO:0030425 9.89 APOE LRRK2 MAPT PRNP TH
3 neuron projection GO:0043005 9.85 APP LRRK2 PARK7 PRKN SLC6A3 TH
4 membrane raft GO:0045121 9.8 APP LRRK2 PARK7 PRNP SLC6A3
5 growth cone GO:0030426 9.73 APP LRRK2 MAPT SNCA
6 presynapse GO:0098793 9.71 PARK7 PRKN SLC6A3
7 neuronal cell body GO:0043025 9.7 APOE LRRK2 MAPT SLC6A3 SNCA SNCAIP
8 postsynapse GO:0098794 9.65 LRRK2 PRNP SNCA
9 synaptic vesicle GO:0008021 9.65 LRRK2 SLC18A2 SNCA SNCAIP TH
10 terminal bouton GO:0043195 9.62 APP LRRK2 SNCA TH
11 nuclear envelope lumen GO:0005641 9.51 APP BCHE
12 axon GO:0030424 9.5 APP LRRK2 MAPT PARK7 SLC6A3 SNCA
13 inclusion body GO:0016234 8.92 LRRK2 PRNP SNCA SNCB
14 mitochondrion GO:0005739 10.13 CYP2D6 LRRK2 MAOB PARK7 PRKN SNCA
15 endoplasmic reticulum GO:0005783 10.11 APOE BCHE CYP2D6 LRRK2 PARK7 PRKN
16 extracellular space GO:0005615 10.11 ACHE ADAMTS2 APOE APP BCHE GBA
17 Golgi apparatus GO:0005794 10.1 ACHE APOE APP LRRK2 PRKN PRNP

Biological processes related to Dementia, Lewy Body according to GeneCards Suite gene sharing:

(show top 50) (show all 64)
id Name GO ID Score Top Affiliating Genes
1 negative regulation of neuron apoptotic process GO:0043524 9.91 APOE PARK7 PRKN SNCA SNCB
2 cellular protein metabolic process GO:0044267 9.91 APOE APP PRKN RPS27A SNCA SNCAIP
3 cellular response to oxidative stress GO:0034599 9.9 LRRK2 PARK7 SNCA
4 mitochondrion organization GO:0007005 9.88 GBA LRRK2 PARK7 PRKN
5 response to oxidative stress GO:0006979 9.88 APOE APP LRRK2 PRKN PRNP
6 positive regulation of proteasomal ubiquitin-dependent protein catabolic process GO:0032436 9.87 GBA LRRK2 PRKN
7 negative regulation of gene expression GO:0010629 9.86 MAPT PARK7 PRKN
8 regulation of autophagy GO:0010506 9.83 LRRK2 MAPT PRKN
9 adult locomotory behavior GO:0008344 9.83 APP PARK7 PRKN SNCA
10 protein destabilization GO:0031648 9.8 PRKN PRNP SNCA
11 locomotory behavior GO:0007626 9.77 APP PRKN SLC18A2 SLC6A3 TH
12 synapse organization GO:0050808 9.76 APP MAPT SNCA SNCB
13 regulation of neurotransmitter secretion GO:0046928 9.74 PRKN SNCA SNCAIP
14 negative regulation of hydrogen peroxide-induced cell death GO:1903206 9.73 LRRK2 PARK7
15 response to corticosterone GO:0051412 9.73 MAOB TH
16 microglial cell activation GO:0001774 9.73 MAPT SNCA
17 cellular response to dopamine GO:1903351 9.73 LRRK2 PRKN
18 negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway GO:1902236 9.73 LRRK2 PARK7 PRKN
19 cellular response to copper ion GO:0071280 9.72 PRNP SNCA
20 supramolecular fiber organization GO:0097435 9.72 MAPT SNCA
21 cellular copper ion homeostasis GO:0006878 9.72 APP PRNP
22 negative regulation of protein processing GO:0010955 9.72 LRRK2 PRNP
23 neurotransmitter biosynthetic process GO:0042136 9.72 ACHE SLC6A3 TH
24 negative regulation of protein phosphorylation GO:0001933 9.72 LRRK2 PARK7 PRKN PRNP SNCA
25 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.71 PARK7 SNCA
26 virion assembly GO:0019068 9.71 APOE RPS27A
27 neurotransmitter catabolic process GO:0042135 9.71 ACHE MAOB
28 amyloid precursor protein metabolic process GO:0042982 9.71 ACHE APOE
29 learning GO:0007612 9.71 BCHE PRKN TH
30 positive regulation of protein metabolic process GO:0051247 9.7 APP GBA
31 regulation of dopamine metabolic process GO:0042053 9.7 PRKN SLC6A3
32 amyloid fibril formation GO:1990000 9.7 APP MAPT
33 monoamine transport GO:0015844 9.69 SLC18A2 SLC6A3
34 positive regulation of protein binding GO:0032092 9.69 LRRK2 PRKN
35 regulation of locomotion GO:0040012 9.68 LRRK2 SNCA
36 mating behavior GO:0007617 9.68 APP TH
37 regulation of mitochondrial fission GO:0090140 9.68 LRRK2 MAPT
38 intracellular distribution of mitochondria GO:0048312 9.67 LRRK2 MAPT
39 dopamine catabolic process GO:0042420 9.67 MAOB SLC6A3
40 dopamine biosynthetic process GO:0042416 9.67 SLC6A3 SNCA TH
41 positive regulation of mitophagy GO:1903599 9.66 PARK7 PRKN
42 dopamine transport GO:0015872 9.65 SLC18A2 SLC6A3
43 negative regulation of long-term synaptic potentiation GO:1900272 9.65 APOE PRNP
44 protein localization to mitochondrion GO:0070585 9.64 LRRK2 PRKN
45 negative regulation of cellular protein metabolic process GO:0032269 9.64 APOE GBA
46 negative regulation of oxidative stress-induced cell death GO:1903202 9.63 PARK7 PRKN
47 negative regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathway GO:1903377 9.61 PARK7 PRKN
48 aminergic neurotransmitter loading into synaptic vesicle GO:0015842 9.61 SLC18A2 TH
49 regulation of synaptic vesicle transport GO:1902803 9.6 LRRK2 PRKN
50 isoquinoline alkaloid metabolic process GO:0033076 9.59 CYP2D6 TH

Molecular functions related to Dementia, Lewy Body according to GeneCards Suite gene sharing:

(show all 17)
id Name GO ID Score Top Affiliating Genes
1 microtubule binding GO:0008017 9.81 LRRK2 MAPT PRNP SNCA
2 enzyme binding GO:0019899 9.7 APP BCHE MAPT PARK7 PRKN SNCA
3 copper ion binding GO:0005507 9.65 PARK7 PRNP SNCA
4 identical protein binding GO:0042802 9.65 APOE APP BCHE LRRK2 MAPT PARK7
5 beta-amyloid binding GO:0001540 9.62 ACHE APOE BCHE PRNP
6 ubiquitin-specific protease binding GO:1990381 9.57 PARK7 PRKN
7 phospholipase binding GO:0043274 9.56 PRKN SNCA
8 tubulin binding GO:0015631 9.56 LRRK2 MAPT PRKN PRNP
9 dopamine binding GO:0035240 9.55 SLC6A3 TH
10 tau protein binding GO:0048156 9.52 APOE SNCA
11 monoamine transmembrane transporter activity GO:0008504 9.49 SLC18A2 SLC6A3
12 lipoprotein particle binding GO:0071813 9.46 APOE MAPT
13 cholinesterase activity GO:0004104 9.43 ACHE BCHE
14 cupric ion binding GO:1903135 9.4 PARK7 PRNP
15 acetylcholinesterase activity GO:0003990 9.37 ACHE BCHE
16 cuprous ion binding GO:1903136 8.92 PARK7 PRNP SNCA SNCB
17 protein homodimerization activity GO:0042803 10.01 ACHE APOE LRRK2 MAOB MAPT PARK7

Sources for Dementia, Lewy Body

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....